COMPOSITIONS AND METHODS OF USING HisGTG TRANSFER RNAS (tRNAs)
AssigneeThoams Jefferson University
InventorIsidore RIGOUTSOS
Life of this patent
Estimating the term…
Abstract
The present invention includes a method for analyzing tRNAHisGTG fragments. In one aspect, the present invention includes a method of identifying a subject in need of therapeutic intervention to treat and/or prevent a disease or condition, disease recurrence, or disease progression comprises characterizing the identity of tRNAHisGTG fragments. The invention further includes diagnosing, identifying or monitoring a disease or condition, a panel of engineered oligonucleotides, a kit for a high-throughput assay, and a method and system for identifying tRNAHisGTG fragments.
Claims22
A method of identifying a subject in need of therapeutic intervention to treat and/or prevent a disease, condition, disease recurrence or disease progression, the method comprising characterizing at least one tRNAHisGTG fragment and its relative abundance isolated from a sample obtained from the subject to identify a signature, wherein, when the signature is indicative of a diagnosis of the disease, condition, disease recurrence or disease progression, treatment of the subject is recommended.
A method of diagnosing, identifying or monitoring a disease or condition in a subject in need thereof, the method comprising:
- hybridizing at least one tRNAHisGTG fragment obtained from a cell obtained from the subject to a panel of oligonucleotides engineered to detect the tRNAHisGTG fragment;
- analyzing levels of the tRNAHisGTG fragment present in the cell;
- wherein a differential in the measured tRNAHisGTG fragment levels compared to a reference is indicative of a diagnosis or identification of breast cancer in the subject;
- and
- providing a treatment regimen to the subject dependent on the differential in the measured tRNAHisGTG fragment levels to the reference.
A set of engineered oligonucleotides comprising a mixture of oligonucleotides that are about 15 to about 50 nucleotides in length and capable of hybridizing at least one tRNAHisGTG fragment.
A method of identifying a cell's tissue of origin to treat and/or prevent a disease or condition, disease recurrence, or disease progression in a subject in need thereof, the method comprising:
- characterizing the identity of at least one tRNAHisGTG fragment and its relative abundance isolated from a cell obtained from the subject to identify a signature, wherein the signature is indicative of the cell's tissue of origin;
- and
- providing a treatment regimen to the subject dependent on the cell's tissue of origin.
Dependencies are inferred from the claim text.